US Pharma MarketingTravere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics pays $112 million upfront to Everest Medicines for ex-China rights to BTK inhibitor civorebrutinib, targeting rare kidney diseases. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari.
The San Diego biotech is doling out $112 million upfront to the Shanghai ...
Source: Endpoints News